LVADs and Impella devices both pump blood on behalf of a failing heart, but they occupy very different roles: an LVAD is a surgically implanted pump designed for months-to-years of support in advanced heart failure, while an Impella is a catheter-based miniature pump intended for hours-to-days of acute circulatory rescue. The two devices differ in size, insertion method, duration, clinical purpose, and the complications they carry. Understanding where each fits helps make sense of a confusing landscape of heart-support technology that can involve one device, the other, or both used in sequence.
What Each Device Actually Is
An LVAD, or left ventricular assist device, is a mechanical pump placed inside or adjacent to the heart through open-chest surgery. It draws blood from the left ventricle and delivers it into the aorta, effectively doing most of the pumping work the left side of the heart can no longer manage. Modern LVADs are continuous-flow centrifugal pumps, a third-generation design that uses a magnetically levitated impeller spinning without physical contact bearings, reducing friction and blood damage compared to older pulsatile models. The pump sits inside the chest, connected by a cable (called a driveline) that exits through the skin and attaches to an external controller and battery pack the patient carries at all times. LVADs were introduced as a bridge to heart transplantation but are now an established long-term alternative, with median survival exceeding five years even in patients who are not transplant candidates.
The Impella is a microaxial flow pump small enough to be threaded through a blood vessel and positioned across the aortic valve so that its inlet sits inside the left ventricle and its outlet sits in the ascending aorta. It works on a principle similar to an Archimedes screw: a tiny motor spins a corkscrew-shaped impeller that propels blood forward, independent of the heart’s own rhythm or electrical activity. Several Impella sizes exist, ranging from models that deliver around two liters per minute of flow up to the Impella 5.5, which can provide over five liters per minute and requires surgical placement through a larger artery. The device is meant to be temporary, typically supporting a patient for days rather than months.
How They Get Into the Body
This is one of the starkest practical differences. LVAD implantation is a major cardiac surgery. Traditionally the surgeon opens the chest through a full median sternotomy, though a less invasive approach through a left thoracotomy has become increasingly popular. Either way, the patient goes on cardiopulmonary bypass, the pump is sewn into the heart’s apex, and an outflow graft is connected to the aorta. Recovery involves days in the intensive care unit and weeks of rehabilitation.
The Impella, by contrast, is usually placed percutaneously, meaning through a puncture in the femoral artery in the groin. A cardiologist advances the device over a guidewire, through the aorta, across the aortic valve, and into the left ventricle, all guided by imaging. The procedure can be done in a catheterization lab without opening the chest. When femoral access is not ideal, perhaps because of peripheral vascular disease or because the clinical team wants the patient to be able to sit up and move, the axillary artery in the upper arm offers an alternative route. A multicenter registry studying this approach found successful device placement in 98 out of 102 attempts, with acceptable bleeding rates despite early experience with the technique.
Duration and Clinical Purpose
The Impella is built for acute, short-term crises. Its most common uses fall into two broad categories. The first is cardiogenic shock, where the heart suddenly cannot pump enough blood to sustain the body’s organs. The Impella can be deployed quickly to stabilize circulation while clinicians figure out the next step, whether that is recovery, surgery, or escalation to a more durable device. The second major use is elective support during high-risk coronary interventions. In patients with severe coronary artery disease and a weakened heart, the Impella can keep blood flowing during complex stent procedures that might otherwise cause dangerous drops in blood pressure. A Polish registry of patients with ejection fractions at or below 30 percent who received Impella support during high-risk multi-vessel procedures reported a procedural success rate above 99 percent.
LVADs, on the other hand, are for patients whose heart failure is advanced, chronic, and not going to resolve with temporary measures. An LVAD can serve as a bridge to transplantation, keeping a patient alive and functional while waiting for a donor heart. It can serve as destination therapy for people who are not transplant candidates. And in a smaller number of cases, it can serve as a bridge to recovery, supporting the heart long enough for it to heal, though in practice this remains uncommon. Real-world registries show LVAD explantation rates below 5 percent, even though focused research cohorts have reported recovery rates as high as 48 to 60 percent, highlighting a gap between what is theoretically possible and what happens in routine clinical care.
How They Help the Heart Differently
Both devices reduce the workload on the left ventricle, but they do so at different scales and with different physiological effects. The Impella actively reduces both the volume and pressure inside the left ventricle while simultaneously boosting blood flow to the rest of the body. By lowering the heart’s oxygen demand and improving the supply of oxygenated blood to the coronary arteries, it can protect heart muscle during acute injury and create conditions for the ventricle to recover. Think of it as giving the heart a short vacation from its heaviest lifting so damaged tissue has a chance to heal.
An LVAD takes over the bulk of left ventricular output on an ongoing basis. In patients with severe heart failure, the native heart may contribute only a fraction of total blood flow, with the LVAD handling the rest. Over time, this sustained unloading can trigger favorable structural changes in the heart muscle. Partial cardiac recovery has been observed in over 30 percent of LVAD recipients, though transitioning from partial to full recovery requires aggressive drug therapy and careful monitoring of heart function parameters before the device can be considered for removal.
One important hemodynamic consequence of LVAD support involves the right side of the heart. By dramatically increasing left ventricular output, the LVAD sends more blood through the lungs and demands more from the right ventricle. In patients whose right ventricle is already borderline, this can tip it into failure. Depending on how right heart failure is defined, somewhere between 5 and 44 percent of LVAD recipients develop this complication, which is associated with worse outcomes. The Impella rarely triggers this problem in the same way, partly because it is temporary and partly because the flow rates involved are lower.
Complications That Come With Each Device
Every mechanical heart support device introduces risks that would not exist without it. The specific complications differ between these two technologies in ways that reflect their designs and durations of use.
Impella-Specific Risks
Because the Impella sits inside a blood vessel and crosses the aortic valve, it can obstruct blood flow to the leg on the side where it was inserted. The reported rate of distal leg ischemia with the Impella CP model runs from about 4 to 17 percent, with higher rates in women (whose femoral arteries tend to be smaller) and in older patients who are more likely to have underlying peripheral vascular disease. Clinicians can mitigate this by placing a distal perfusion catheter that routes blood around the device to the leg, a strategy that has become standard practice at many centers.
Hemolysis, the mechanical destruction of red blood cells by the spinning impeller, is another concern. When the pump is stable and well-positioned, hemolysis tends to be mild. But if the device migrates or the patient moves in a way that destabilizes the pump, hemolysis can spike, leading to anemia and kidney stress from the released hemoglobin. Bleeding can also occur at the access site or elsewhere, and managing it requires balancing the anticoagulation the device needs to prevent clots against the bleeding risk the patient already faces.
LVAD-Specific Risks
LVADs carry a different complication profile shaped by their permanence and the intensity of the surgery. Stroke is one of the most feared complications. In one study of nearly 500 LVAD patients, about 12 percent developed an ischemic stroke. These strokes clustered around identifiable triggers: roughly a third occurred in the days immediately after surgery, another third were linked to clots forming on the pump itself, and over half happened while the patient’s blood-thinning regimen was not at the right level. Bloodstream infections were also common among stroke patients, present in about a fifth of cases, reinforcing the idea that these strokes arise from a prothrombotic state rather than random bad luck.
Infection along the driveline, the cable that exits the skin to connect the internal pump to external batteries, is a chronic challenge unique to LVADs. The exit site is a permanent opening in the skin and a persistent entry point for bacteria. Patients and their caregivers must perform meticulous daily wound care for as long as the device is in place, which can be years.
Gastrointestinal Bleeding and Acquired von Willebrand Syndrome
One of the more counterintuitive LVAD complications deserves its own discussion. Continuous-flow LVADs shear blood at high speeds, and this mechanical force physically breaks apart large molecules of von Willebrand factor, a protein essential for normal blood clotting. In most LVAD patients, the von Willebrand factor rapidly loses the large structures it needs to function properly, leading to a condition called acquired von Willebrand syndrome. One study confirmed a diagnosis of von Willebrand syndrome type 2 in every patient after LVAD implantation, and the condition reversed after the device was removed. In another cohort, all 37 patients showed significant loss of high-molecular-weight von Willebrand factor multimers within 30 days of continuous-flow LVAD placement, and about a quarter experienced bleeding complications afterward.
This creates a difficult clinical paradox. The LVAD needs blood thinners to prevent pump clots and stroke, but the device itself is simultaneously degrading one of the body’s clotting proteins. The result is an elevated risk of gastrointestinal bleeding that is one of the most common reasons LVAD patients end up back in the hospital. The Impella can also cause hemolysis and bleeding, but because it is temporary, it does not produce the sustained von Willebrand factor degradation that makes LVAD-related GI bleeding so persistent.
Using Impella as a Bridge to LVAD
In clinical practice, these devices are not always an either-or choice. Patients who arrive in severe cardiogenic shock may be too unstable for the major surgery an LVAD requires. Placing an Impella first can stabilize their circulation, allow their other organs to recover from the shock state, and buy time for the surgical team to plan a safer LVAD implant. This “bridge to bridge” strategy has gained traction, and the data look encouraging.
A Japanese analysis of nearly a thousand patients receiving durable LVADs found that those who were first stabilized with an Impella had the lowest mortality during subsequent LVAD support, at 8 percent over a median follow-up of about three years, compared to 21 percent in a group bridged with other temporary support devices. The trend toward better survival with the Impella-bridge approach was strong, though it did not quite reach conventional statistical significance in the fully adjusted analysis. The strategy became more common after the introduction of the Impella 5.5, which provides enough flow to meaningfully support a patient in deep shock while keeping the option of a durable device open.
Not every escalation from Impella to LVAD goes smoothly. In a single-center experience, three patients on the Impella 5.5 deteriorated enough to require upgrade to a HeartMate 3 LVAD. One survived to discharge, but the other two continued to decline despite maximal support including biventricular assist devices, reflecting how fragile these patients can be. Right ventricular failure was present in two-thirds of the patients who made this transition, underscoring why the right side of the heart is a recurring concern in advanced heart failure management.
Anticoagulation and Day-to-Day Management
Both devices require anticoagulation to prevent blood clots from forming on their mechanical surfaces, but the logistics differ substantially. The Impella uses a heparin-containing purge solution that flows continuously through the device to prevent thrombosis and maintain proper pump function. Because the Impella is used in a hospital setting for short periods, anticoagulation management is handled by the bedside team in real time, with frequent blood tests and dose adjustments.
LVAD anticoagulation is a longer-term balancing act. Patients typically take warfarin daily and often aspirin as well, with regular blood tests to keep their clotting time within a target range. Too little anticoagulation raises the risk of pump thrombosis and stroke; too much raises the risk of bleeding, especially given the acquired von Willebrand syndrome described above. This balancing act does not end. It continues for the entire duration of LVAD support, which can be years. For patients receiving an LVAD as destination therapy, outpatient management becomes a critical ongoing effort to achieve the best possible outcomes over the long haul.
Living With an LVAD Versus Recovering From an Impella
For patients, the lived experience of these two devices could hardly be more different. An Impella insertion is an acute event. You are in the hospital, typically in an ICU or catheterization lab, and when the device comes out, you recover from the access-site puncture and whatever cardiac event brought you there in the first place. There is no device to take home.
An LVAD fundamentally changes daily life. You carry batteries and a controller everywhere. You cannot submerge the driveline exit site in water, which means no swimming and modified bathing routines. You or a caregiver must inspect and dress the driveline exit site daily. Power must always be available, so travel requires planning around battery life and backup equipment. Despite these constraints, most LVAD patients experience a dramatic improvement in how they feel and what they can do physically. Studies describe a doubling in functional capacity even among patients receiving the device as permanent therapy. Many return to work, travel, and engage in moderate physical activity. The trade-off is real autonomy gains at the cost of constant device awareness.
Patient Selection and Risk Stratification
Choosing between these devices, or sequencing them, depends heavily on the clinical scenario and the patient’s trajectory. Patients classified at the most critical level of heart failure, sometimes described as being in a “crash and burn” state, often cannot tolerate immediate LVAD surgery. For them, temporary mechanical support with an Impella or another short-term device may be the only viable first step, stabilizing organ function before a durable device can be safely implanted. The challenge lies in deciding when a patient has recovered enough from their acute crisis to survive LVAD surgery but not so much that they no longer need it.
For patients with chronic advanced heart failure who are declining more gradually, the calculation is different. They may go directly to LVAD implantation without needing temporary support first. The decision between bridge-to-transplant and destination therapy depends on whether the patient is a transplant candidate, which involves evaluating factors far beyond the heart itself, including kidney function, body size, psychosocial support, and the presence of other medical conditions that might disqualify them from the transplant list. Some patients start on an LVAD with one intended goal and switch strategies later as their clinical picture evolves.
How LVAD Technology Has Evolved
The LVADs in use today bear little resemblance to the earliest versions. First-generation devices were pulsatile pumps that used a diaphragm and artificial valves to mimic the heart’s natural fill-and-squeeze cycle. They were bulky, mechanically complex, and prone to wear. Second-generation devices moved to continuous flow using a rotor that spun blood in an axial direction, dramatically shrinking the pump and improving durability. The current third generation uses centrifugal flow with a magnetically levitated impeller, eliminating contact bearings entirely. This reduces friction, heat, and blood damage, and has translated into better survival and fewer pump-related complications.
The Impella has also seen iterative improvements, with newer models offering higher flow rates and more refined catheter designs. The Impella 5.5, which requires surgical placement through the axillary artery rather than percutaneous femoral access, expanded the device’s reach into patients with more severe shock who need greater circulatory support than the smaller percutaneous models can provide. This blurred the boundary between “percutaneous temporary device” and “surgically placed support,” reflecting a broader trend in the field toward tailoring the level of support to the individual patient’s needs rather than choosing rigidly between device categories.